@article{b91ced19cc3e4735be106a4d9e7e5ba0,
title = "Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase",
abstract = "A stratified medicine approach for the treatment of psoriasis promises greater certainty of clinical decision making through prediction of response on the basis of clinical, pharmacological, and -omics data from an individual patient. As yet, there is no predictive model for treatment response in routine clinical use for psoriasis. The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium is a United Kingdom Medical Research Council‒funded, academic‒industrial stratified medicine consortium established with the objective of discovering the predictors and stratifiers of response of psoriasis to biologic therapies. A showcase meeting was convened and attended by 80 stakeholders at the Royal College of Physicians, London, United Kingdom on 18 November 2019. The purpose was to disseminate the research findings from the PSORT consortium discovered thus far. This report summarizes the presentations made on the day and the significant advances made by PSORT toward a stratified medicine approach to the management of psoriasis.",
author = "{PSORT consortium} and Yiu, {Zenas Z N} and Barker, {Jonathan N W N} and Barnes, {Michael R} and {Di Meglio}, Paola and Richard Emsley and Reynolds, {Nick J} and Smith, {Catherine H} and Warren, {Richard B} and Griffiths, {Christopher E M}",
note = "Funding Information: Psoriasis Stratification to Optimise Relevant Therapy (PSORT) is funded by a Medical Research Council Stratified Medicine award (MR/L011808/1), with cofunding from consortium partners: the Psoriasis Association, the British Association of Dermatologists, AbbVie, Becton Dickinson and Company, Celgene, Eli Lilly and Company, GlaxoSmithKline, Janssen Research & Development LLC, LEO Pharma, Medimmune, Novartis Pharmaceuticals UK, and Pfizer. PSORT has received support from the National Institute for Health Research (NIHR) Biomedical Research Centres at King's College London and Guy and St Thomas NHS Foundation Trust, Manchester and Newcastle. The British Association of Dermatologists Biologics and Immunomodulators Register is coordinated by the University of Manchester (United Kingdom) and is funded by the British Association of Dermatologists. The PSORT Showcase was funded through contributions from the British Association of Dermatologists and the International Psoriasis Council and Galderma. CEMG is an NIHR emeritus senior investigator, NJR is an NIHR senior investigator, and ZZNY is an NIHR academic clinical lecturer. CEMG and RBW are funded in part by the NIHR Manchester Biomedical Research Centre. NJR is funded in part by the NIHR Newcastle Biomedical Research Centre. Partners of the PSORT consortium are AbbVie, the British Association of Dermatologists, Becton Dickinson and Company, Celgene, GlaxoSmithKline, Guy and St Thomas NHS Foundation Trust, Eli Lilly, Janssen Research & Development, King's College London, LEO Pharma, MedImmune, Novartis Pharmaceuticals UK, Pfizer Italy, the Psoriasis Association, Qiagen Manchester, Queen Mary University of London (United Kingdom), the Royal College of Physicians (London, United Kingdom), Sanquin Blood Supply Foundation, the University of Liverpool (United Kingdom), the University of Manchester (United Kingdom), and Newcastle University (Newcastle upon Tyne, United Kingdom). Conceptualization: JNWNB, MRB, PDM, RE, NJR, CHS, RBW, CEMG; Formal Analysis: ZZNY, PDM, RE; Funding Acquisition: JNWNB, MRB, NJR, CHS, RBW, CEMG; Investigation: ZZNY, PDM; Methodology: ZZNY, MRB, PDM, RE; Supervision: JNWNB, MRB, PDM, RE, NJR, CHS, RBW, CEMG; Visualization: ZZNY; Writing ? Original Draft Preparation: ZZNY; Writing ? Review and Editing: ZZNY, JNWNB, MRB, PDM, RE, NJR, CHS, RBW, CEMG Funding Information: Psoriasis Stratification to Optimise Relevant Therapy (PSORT) is funded by a Medical Research Council Stratified Medicine award (MR/L011808/1), with cofunding from consortium partners: the Psoriasis Association , the British Association of Dermatologists, AbbVie, Becton Dickinson and Company, Celgene, Eli Lilly and Company , GlaxoSmithKline , Janssen Research & Development LLC, LEO Pharma, Medimmune, Novartis Pharmaceuticals UK, and Pfizer. PSORT has received support from the National Institute for Health Research (NIHR) Biomedical Research Centres at King{\textquoteright}s College London and Guy and St Thomas NHS Foundation Trust, Manchester and Newcastle. The British Association of Dermatologists Biologics and Immunomodulators Register is coordinated by the University of Manchester (United Kingdom) and is funded by the British Association of Dermatologists. The PSORT Showcase was funded through contributions from the British Association of Dermatologists and the International Psoriasis Council and Galderma. CEMG is an NIHR emeritus senior investigator, NJR is an NIHR senior investigator, and ZZNY is an NIHR academic clinical lecturer. CEMG and RBW are funded in part by the NIHR Manchester Biomedical Research Centre. NJR is funded in part by the NIHR Newcastle Biomedical Research Centre. Partners of the PSORT consortium are AbbVie, the British Association of Dermatologists, Becton Dickinson and Company, Celgene, GlaxoSmithKline, Guy and St Thomas NHS Foundation Trust, Eli Lilly, Janssen Research & Development, King's College London, LEO Pharma, MedImmune, Novartis Pharmaceuticals UK, Pfizer Italy, the Psoriasis Association, Qiagen Manchester, Queen Mary University of London (United Kingdom), the Royal College of Physicians (London, United Kingdom), Sanquin Blood Supply Foundation, the University of Liverpool (United Kingdom), the University of Manchester (United Kingdom), and Newcastle University (Newcastle upon Tyne, United Kingdom). Funding Information: CEMG reported receiving honoraria and/or research grant support (University of Manchester, United Kingdom) from AbbVie, Almirall, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, the LEO Foundation, Eli Lilly, Nestle Skin Health, Novartis, Pfizer, Sandoz, Sun Pharma, and UCB Pharma. NJR reported receiving honoraria, travel support, and/or research grants (Newcastle University, Newcastle upon Tyne, United Kingdom) from AbbVie, Almirall, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Janssen, the LEO Foundation, Novartis, PSORT partners ( www.PSORT.org.uk ), Pfizer, Sanofi Genzyme Regeneron, Stiefel GlaxoSmithKline, and UCB Pharma. JNWNB reported receiving honoraria, travel support, and/or research grants (King{\textquoteright}s College London, United Kingdom) from AbbVie, Pfizer, Almirall, Amgen, Bristol-Myers Squibb, Celgene, LEO Pharma, Novartis, Janssen, Roche, Regeneron, Eli Lilly, UCB Pharma, Samsung, Sienna, Sun Pharma, Boehringer Ingelheim, and GlaxoSmithKline. RBW reported receiving honoraria, research grants, and/or consulting fees from AbbVie, Almirall, Amgen, Arena, Avillion, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sanofi, Xenoport, and UCB Pharma. CHS reported receiving departmental research funding from AbbVie, GlaxoSmithKline, Novartis, Pfizer, Regeneron, Roche, and Medical Research Council consortium, which had several industry partners (see psort.org.uk). PDM has received research grants from UCB and consultancy and/or speaker honoraria from Novartis, UCB, and Janssen. The remaining authors state no conflict of interest. Publisher Copyright: {\textcopyright} 2021 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = aug,
doi = "10.1016/j.jid.2021.02.746",
language = "English",
volume = "141",
pages = "1872--1878",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "8",
}